Who are Labinic (R) probiotic mixture's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Akkermansia muciniphila + Infliximab, "AS-Probionorm", Mesalazine plus Lactobacillus casei, Synbiotic 2000, Probiotic Vivomixx, INF108F probiotic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/labinic-r-probiotic-mixture.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Labinic (R) probiotic mixture — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Labinic (R) probiotic mixture (Labinic (R) probiotic mixture) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology / Immunology.

phase 3 Probiotic Gastroenterology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

Labinic (R) probiotic mixture (Labinic (R) probiotic mixture) — Haydom Lutheran Hospital. Labinic is a probiotic mixture that restores beneficial gut microbiota to improve intestinal health and immune function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Labinic (R) probiotic mixture TARGET	Labinic (R) probiotic mixture	Haydom Lutheran Hospital	phase 3	Probiotic
Akkermansia muciniphila + Infliximab	Akkermansia muciniphila + Infliximab	Chinese Medical Association	marketed	Combination therapy: probiotic + TNF-α inhibitor	TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)
"AS-Probionorm"	"AS-Probionorm"	Industrial Microbiology LLP	marketed	Probiotic
Mesalazine plus Lactobacillus casei	Mesalazine plus Lactobacillus casei	Hospital Cristo Re	marketed	Anti-inflammatory agent plus probiotic combination
Synbiotic 2000	Synbiotic 2000	Beth Israel Medical Center	marketed	Synbiotic (prebiotic + probiotic combination)
Probiotic Vivomixx	Probiotic Vivomixx	University of Milan	marketed	Probiotic
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Labinic (R) probiotic mixture — Competitive Intelligence Brief. https://druglandscape.com/ci/labinic-r-probiotic-mixture. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing